GSK boosts 2031 revenue target to over £40bn following robust Q4 results
Pharmaceutical titan GSK has raised its 2031 sales forecast to over £40bn, an increase from the previously projected £38bn, following a stronger-than-anticipated performance in the fourth quarter.
The London-listed pharmaceutical behemoth disclosed core earnings per share of 23.2p for the quarter, which, despite being a roughly 20% decline year-on-year, exceeded the analysts' expectations of 19p, as reported by City AM.
For the entire year of 2024, GSK reported core earnings per share of 159.3p, marking a 10% rise at constant exchange rates. Turnover climbed by seven percent at constant exchange rates to £31.4bn, or by eight percent when excluding sales
Recommend
Vitality reports £168k loss despite revenue boost to nearly £1bn in 2024
2025-04-15 11:56:11
2025-04-15 11:56:11
Go ahead for new £1.25bn electric arc furnace at Port Talbot
2025-04-15 11:56:11
2025-04-15 11:56:11
North Wales port to create 300 jobs in major expansion
2025-04-15 11:56:11
2025-04-15 11:56:11
College group NCG reports sound finances despite funding clawback
2025-04-15 11:56:11
2025-04-15 11:56:11
Moonpig founder and former Dragons' Den star opens new Wiltshire business school
2025-04-15 11:56:11
2025-04-15 11:56:11
Anglo American presses ahead with demerger of platinum business
2025-04-15 11:56:11
2025-04-15 11:56:11
Alton Towers operator Merlin Entertainments names new full-time chief executive
2025-04-15 11:56:11
2025-04-15 11:56:11
UK Government achieves NHS appointment target early, yet challenges remain
2025-04-15 11:56:11
2025-04-15 11:56:11
Newcastle canning company CRL Foods gets £1m Northern Powerhouse investment
2025-04-15 11:56:11
2025-04-15 11:56:11
East Yorkshire tour company creates Star Bus for global superstar Teddy Swims
2025-04-15 11:56:11
2025-04-15 11:56:11
